Long-term efficacy and safety results: Can enzalutamide challenge the dogma of androgen deprivation therapy in Hormone-naïve prostate cancer?

Laurence Albiges; Yohann Loriot; Christophe Massard; Karim Fizazi

doi:10.1016/j.eururo.2015.04.019

Long-term efficacy and safety results: Can enzalutamide challenge the dogma of androgen deprivation therapy in Hormone-naïve prostate cancer?

Laurence Albiges, Yohann Loriot, Christophe Massard, Karim Fizazi

Résultats de recherche: Contribution à un journal › Editorial

langue originale	Anglais
Pages (de - à)	802-804
Nombre de pages	3
journal	European Urology
Volume	68
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.eururo.2015.04.019
état	Publié - 1 nov. 2015

Accès au document

10.1016/j.eururo.2015.04.019

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{cc42674b5ff14a7481c0ace7f616ee65,

title = "Long-term efficacy and safety results: Can enzalutamide challenge the dogma of androgen deprivation therapy in Hormone-na{\"i}ve prostate cancer?",

author = "Laurence Albiges and Yohann Loriot and Christophe Massard and Karim Fizazi",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.eururo.2015.04.019",

language = "English",

volume = "68",

pages = "802--804",

journal = "European Urology",

issn = "0302-2838",

number = "5",

}

TY - JOUR

T1 - Long-term efficacy and safety results

T2 - Can enzalutamide challenge the dogma of androgen deprivation therapy in Hormone-naïve prostate cancer?

AU - Albiges, Laurence

AU - Loriot, Yohann

AU - Massard, Christophe

AU - Fizazi, Karim

PY - 2015/11/1

Y1 - 2015/11/1

UR - http://www.scopus.com/inward/record.url?scp=84942987867&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2015.04.019

DO - 10.1016/j.eururo.2015.04.019

M3 - Editorial

C2 - 25922192

AN - SCOPUS:84942987867

SN - 0302-2838

VL - 68

SP - 802

EP - 804

JO - European Urology

JF - European Urology

IS - 5

ER -